MRZK Pharma
ActiveSummary
MRZK Pharma has been active since 1989 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €556k and a net result of €36k. Equity is shrinking by ~9% per year across the filed fiscal years. Its solvency ranks better than 87% of 10359 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
78
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability75=
Solvency100=
Growth32=
Track record100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40k at 30 days acceptable
Liquidity ample (current ratio 4.29 against 4.07 in 2024; short-term debt: 22.9% and cash: 3% of total assets), and 22.9% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
77.1%
Return on assets
5%
Age of the figures
9 mo
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €556k
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 12-05-2026, 80 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
80 d early
2024
45 d early
2023
50 d early
2022
52 d early
2021
54 d early
2020
47 d early
2019
18 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€556k▲ 6.9%
2024 · €520k
2018: €1.31M
2019: €1.35M
2020: €1.41M
2021: €1.51M
2022: €1.61M
2023: €486k
2024: €520k
2018 → 2025
Total assets
€721k▲ 5.3%
2024 · €685k
2018: €1.39M
2019: €1.45M
2020: €1.52M
2021: €1.63M
2022: €1.75M
2023: €682k
2024: €685k
2018 → 2025
Net result
€36k▲ 4.9%
2024 · €34k
2018: €48k
2019: €40k
2020: €62k
2021: €98k
2022: €103k
2023: €62k
2024: €34k
2018 → 2025
Working capital
€543k▲ 7.8%
2024 · €503k
2018: €1.29M
2019: €1.33M
2020: €1.39M
2021: €1.49M
2022: €1.60M
2023: €470k
2024: €503k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€1.51M-€1.61M▲ 6.9%€486k▼ 69.8%€520k▲ 7.0%€556k▲ 6.9%
Operating result€119k-€116k▼ 1.9%€60k▼ 48.8%€34k▼ 43.0%€41k▲ 20.8%
Net result€98k-€103k▲ 5.4%€62k▼ 39.7%€34k▼ 45.1%€36k▲ 4.9%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 21% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €721k
Fixed assets
€14k ▼ 20.6%
Current assets
€708k ▲ 6.0%
Equity and liabilities €721k
Equity
€556k ▲ 6.9%
Debt
€165k ▲ 0.5%
Debt's share of the balance-sheet total falls from 24.0% to 22.9%. Equity and debt are higher.
Key figures and ratios
EBITDA
€47k▲
2024 · €39k
Cash flow
€42k▲
2024 · €40k
Current ratio
4.29▲
2024 · 4.07
Quick ratio
3.76▲
2024 · 3.53
Debt to equity
0.30▼
2024 · 0.32
ROE
6.4%▼
2024 · 6.6%
ROA
5.0%▼
2024 · 5.0%
Interest coverage
73.09▼
2024 · 83.09
Debt ≤ 1 year
€165k▲
2024 · €164k
Income taxes
€14k▲
2024 · €13k
Staff costs
€162k▲
2024 · €129k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 43 lines
Balance sheet
Code20242025
Assets
Total assets20/58€685k€721k▲
Fixed assets21/28€17k€14k▼
Tangible fixed assets22/27€16k€12k▼
Plant, machinery and equipment23€5k€3k▼
Furniture and vehicles24€8k€8k▼
Other tangible fixed assets26€2k€1k▼
Financial fixed assets28€2k€2k=
Current assets29/58€667k€708k▲
Stocks and contracts in progress3€88k€88k▲
Stocks30/36€88k€88k▲
Amounts receivable within one year40/41€556k€598k▲
Trade receivables40€221k€239k▲
Other amounts receivable41€335k€360k▲
Cash at bank and in hand54/58€24k€22k▼
Equity and liabilities
Total equity and liabilities10/49€685k€721k▲
Equity10/15€520k€556k▲
Contributions10/11€19k€19k=
Reserves13€502k€538k▲
Tax-exempt reserves132€8k€8k=
Distributable reserves133€494k€530k▲
Amounts payable17/49€164k€165k▲
Amounts payable within one year42/48€164k€165k▲
Trade debts44€149k€146k▼
Suppliers440/4€149k€146k▼
Taxes, remuneration and social security45€15k€19k▲
Remuneration and social security454/9€15k€19k▲
Income statement
Code20242025
Remuneration, social security and pensions62€129k€162k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€5k€6k▲
Other operating charges640/8€2k€1k▼
Gross operating margin9900€170k€211k▲
Operating profit (loss)9901€34k€41k▲
Financial income75/76B€14k€9k▼
Recurring financial income75€14k€9k▼
Financial charges65/66B€474€650▲
Recurring financial charges65€474€650▲
Profit (loss) for the period before taxes9903€47k€49k▲
Income taxes67/77€13k€14k▲
Profit (loss) for the period9904€34k€36k▲
Profit (loss) for the period to be appropriated9905€34k€36k▲
Appropriation of the result
Profit (loss) to be appropriated9906€34k€36k▲
Transfer to equity691/2€34k€36k▲
To other reserves6921€34k€36k▲
Social balance
Average headcount (FTE)90872.82.8=
The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
12-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
16-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Weakest financial yearnet €34k ▼45.1%
Net result drops to €34k, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €500kEq €520k ▲7%
7 profitable years in a row build equity to €520k.
11-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
09-06
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Highest result since 2018net €103k ▲5.4%
Net result €103k, the highest in the series.
07-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
14-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
13-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
09-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
28-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
10-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Hamme (Vl.) · 1 establishment unit since 1990
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Dorp 119220 Hamme (Vl.)Ground area
991 m²
Building footprint
328 m²
Volume, LiDAR
2,161 m³
Parcel 42014B1001/00P000, Flanders · tallest building 10.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
MRZK Pharma
since 19902.046.399.694
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 42014B1001/00P000 | Flanders | 991 m² | 2 · 328 m² | 10.9 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).
Recognitions · licences · registrations
Food safety, FASFC
1 siteHamme (O.-Vl.)2.046.399.694
Similar companies · same sector, comparable size
PHARMACIE DEPREZ
BE 0671.734.995
Charleroi · Eq €556,298
Pharmacie dejardin
BE 0446.901.764
Beauraing · Eq €556,154
P.J. VLEUGELS et Cie
BE 0416.084.270
Frameries · Eq €556,574
Apotheek Heleen Mylle
BE 0811.322.945
Anzegem · Eq €557,057
LS Pharma
BE 0779.459.534
Gembloux · Eq €555,475
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,314 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-12-1989
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 36 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.